Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CLBS

Caladrius Biosciences (CLBS) Stock Price, News & Analysis

Caladrius Biosciences logo

About Caladrius Biosciences Stock (NASDAQ:CLBS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.43
$8.38
52-Week Range
N/A
Volume
466,373 shs
Average Volume
522,308 shs
Market Capitalization
$26.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Receive CLBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLBS Stock News Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
CLBS Caladrius Biosciences, Inc.
See More Headlines

CLBS Stock Analysis - Frequently Asked Questions

Caladrius Biosciences, Inc. (NASDAQ:CLBS) announced its earnings results on Thursday, November, 4th. The biotechnology company reported ($1.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.95) by $0.15.

Caladrius Biosciences's stock reverse split on the morning of Thursday, September 15th 2022. The 1-15 reverse split was announced on Thursday, September 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Caladrius Biosciences investors own include Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI), HubSpot (HUBS), Alphabet (GOOG), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
11/04/2021
Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Miscellaneous Health & Allied Services
Sub-Industry
N/A
Current Symbol
NASDAQ:CLBS
Employees
27
Year Founded
2006

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-27,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.54 per share
Price / Book
N/A

Miscellaneous

Free Float
59,250,000
Market Cap
$26.05 million
Optionable
Optionable
Beta
0.91

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:CLBS) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners